-
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Friday, June 21, 2024 - 11:42am | 718Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field. Most recently,...
-
Why This Moderna Analyst Is Turning Bullish On Drugmaker's Pipeline
Monday, December 19, 2022 - 11:33am | 259Shares of Moderna Inc (NASDAQ: MRNA) rallied in premarket trading on Monday. While the COVID-19 story has become old, a new candidate in Moderna’s pipeline is likely to be a catalyst for its stock, according to Jefferies. The Moderna Analyst: Michael Yee upgraded Moderna from Hold to Buy...
-
Why Shares Of COVID-19 Vaccine Maker Moderna Are Shooting Higher On Monday
Monday, December 19, 2022 - 8:14am | 282Shares of coronavirus vaccine maker Moderna Inc. (NASDAQ: MRNA) were rallying in premarket trading on Monday. What Happened: Jefferies analyst Michael Yee upgraded shares of Moderna from Neutral to Buy and raised the price target from $170 to $275, suggesting 42% upside from current levels....
-
Why Moderna Stock Is Trading Higher Today
Monday, July 19, 2021 - 10:30am | 169Moderna Inc (NASDAQ: MRNA) is trading higher Monday morning amid renewed COVID-19 concerns. The recent spread of the COVID-19 Delta variant is a major concern. Delta first appeared in India at the end of 2020. The highly contagious COVID-19 variant surfaced in the United States...
-
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Monday, September 14, 2020 - 12:47pm | 901Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...
-
Moderna Analyst: Phase 3 Coronavirus Data Could Arrive As Soon As October
Monday, August 3, 2020 - 1:43pm | 546Moderna Inc (NASDAQ: MRNA) initiated a large-scale Phase 3 study of its coronavirus vaccine candidate in mid-July. An analyst at Jefferies conducted a statistical analysis of the study design to arrive at the likely timing of the data readout — whether they think the study will achieve...
-
Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B+ In Orders Over Next Few Years
Monday, July 13, 2020 - 12:30pm | 393Moderna Inc (NASDAQ: MRNA) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program. The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target. The...
-
Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill
Friday, August 9, 2019 - 10:52am | 477Shares of the mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) were pulling back to their lowest level since early January on Friday. What Happened Amarin said Thursday after the market close that it was notified by the FDA of the agency's intention to hold an Adcom meeting for...
-
Jefferies On Gilead: 'We See Better Days Ahead'
Friday, January 26, 2018 - 2:48pm | 386The new year has brought relief to Gilead Sciences, Inc. (NASDAQ: GILD)’s long-pressured stock, and one analyst projects a continuation in its U-shaped recovery. The Rating Jefferies analyst Michael Yee upgraded Gilead to Buy and raised the price target from $87 to $95. The Thesis...
-
3 Highlights From A Spark Therapeutics Fireside Chat
Friday, October 13, 2017 - 9:36am | 320Analysts at Jefferies hosted a fireside chat-themed conversation with Spark Therapeutics Inc (NASDAQ: ONCE) to discuss the company's successes from Thursday's FDA panel. Analyst Michael Yee maintains a Buy rating on Spark's stock with an unchanged $95 price target and noted three main...
-
RBC Hints At Potential M&A For Kite Pharma
Monday, March 6, 2017 - 2:10pm | 358Michael Yee of RBC Capital Markets reiterated an Outperform rating on Kite Pharma Inc (NASDAQ: KITE) with a price target boosted to $95 from a previous $85. According to Yee, competition from Novartis AG (ADR)'s (NYSE: NVS) CTL019 CAR-T isn't too concerning as Novartis' prior studies...
-
There's A Historical Precedent For The Biotech Selloff
Wednesday, February 17, 2016 - 11:15am | 298There’s no question it has been a rough few months for biotech investors. In a new report, RBC Capital Markets analyst Michael Yee looked at whether the biotech sector has endured similar selloffs in the past. According to Yee, the biotech sector has dropped below its current forward PE...
-
M&A In Small-, Mid-Cap Biotechs Isn't Slowing Down
Monday, December 14, 2015 - 12:59pm | 512Michael Yee of RBC Capital Markets commented in a note that M&A activity within small- and mid-cap healthcare companies "doesn't seem to be slowing down much." Yee added that "good" late-stage and de-risked drugs should command a high value, regardless of any political uncertainty. The latest...
-
Is More M&A On The Way For Large-Cap Biotechs?
Tuesday, July 28, 2015 - 1:18pm | 407Following the recently-announced Teva Pharmaceutical (NYSE: TEVA) buyout of Allergan Plc (NYSE: AGN), RBC Capital Markets analyst Michael Yee released a report discussing the potential for large-cap biotech companies to become buyout targets for specialty pharmaceutical companies. According to...
-
RBC's Michael Yee Still Sees Value in Biogen's Long-Term Pipeline
Friday, July 24, 2015 - 12:45pm | 308Biogen Inc (NASDAQ: BIIB) shares are being killed today after the company reported earnings that missed expectations and lowered guidance. Shares are trading down by more than 18 percent on Friday to below $315 at last. Michael Yee at RBC Capital Markets said that the stock may "take a bit of time...